Claims for Patent: 10,550,186

Summary for Patent: 10,550,186

Title:	Cancer therapy targeting intercellular adhesion molecule 4 (ICAM4)
Abstract:	Methods for treating cancer, e.g., in conjunction with anti-cancer therapy, like immunotherapy, and for identifying candidate therapeutic agents, by targeting ICAM4. While MDSCs in mice have been extensively characterized, their human counterparts are not well defined, and cell markers present in mice are not always usable in humans. MDSCs have been described as a heterogenous population of myeloid derived cells with immune suppressive capacity (5, 9, 40, 41). Recent renewed interest in the role of MDSC accumulation in human tumors has resulted in the increased need to define these cells better in order to target them for therapeutic intervention.
Inventor(s):	Sukhatme; Vikas P. (Newton, MA), Husain; Zaheed (Medford, MA)
Assignee:	Beth Israel Deaconess Medical Center, Inc. (Boston, MA)
Application Number:	15/532,844
Patent Claims:	1. A method of treating cancer in a subject, the method comprising: detecting a level of ICAM4+ MDSC in a sample from the subject; comparing the level of ICAM4+ MDSC in the sample to a reference level of ICAM4+ MDSC; selecting a subject who has a level of ICAM4+ MDSC above a reference level for treatment with a therapy that reduces levels of MDSCs, and administering the therapy that reduces levels of MDSCs to the subject. 2. The method of claim 1, wherein the cancer is a solid cancer of epithelial origin. 3. The method of claim 1, wherein the cancer is characterized by the presence of ICAM4+ myeloid derived suppressor cells (MDSC) in the cancer tissue. 4. The method of claim 1, wherein the therapy that reduces levels of MDSCs is selected from the group consisting of Phosphodiesterase-5 (PDE-5) inhibitors; Synthetic triterpenoids; Cyclooxygenase 2 (COX2) inhibitors; arginase inhibitors; NF-.kappa.B inhibitors; inhibitors of Nitric oxide synthase; inhibitors of colony stimulating factors and their receptors; histamine or H2 blockers; IL-17; all-trans retinoic acid (ATRA); Vitamin D3 or Vitamin A; TLR9 ligand agonists; Nitro-Bisphosphonates (N-Bisphosphonates); inhibitors of STAT3 activation; and platinum agents; Sunitinib; Gemcitabine; 5-Fluorouracil (5-FU); paclitaxel; heat shock protein 90 (HSP90) inhibitors; IL-13 linked to Pseudomonas exotoxin (IL-13-PE); and anti-Gr1+ antibodies.

Details for Patent 10,550,186

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924		2035-12-02
Novo Nordisk Inc.	TRETTEN	coagulation factor xiii a-subunit (recombinant)	For Injection	125398	December 23, 2013		2035-12-02

International Patent Family for US Patent 10,550,186

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016089950
United States of America	2017362320